$2M Bet On Biohaven? Check Out These 4 Stocks Insiders Are Buying
Portfolio Pulse from Lisa Levin
Insiders at Compass Diversified (CODI), Zebra Technologies (ZBRA), Cerevel Therapeutics (CERE), and Biohaven Ltd. (BHVN) have recently made significant stock purchases. This could indicate their confidence in the companies' prospects. However, Compass Diversified and Biohaven posted losses for the second quarter, while Zebra Technologies reported a decline in net sales. Cerevel Therapeutics posted a narrower-than-expected quarterly loss.
August 08, 2023 | 11:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
President and CEO Ronald Renaud Jr bought 83,857 shares of Cerevel Therapeutics at an average price of $23.96. The company posted a narrower-than-expected quarterly loss.
The insider purchase and the narrower-than-expected loss could positively impact the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Director John Childs bought 100,000 shares of Biohaven at an average price of $19.78. The company posted a wider-than-expected second-quarter loss.
While the insider purchase indicates confidence, the wider-than-expected loss may negatively impact the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
10% owner Elias Sabo acquired 50,000 shares of Compass Diversified at an average price of $22.36. The company posted a loss for the second quarter.
While the insider purchase indicates confidence, the company's recent loss may negatively impact the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
Executive Chair Anders Gustafsson and CEO Bill Burns acquired a total of 5,100 shares of Zebra Technologies at an average price of $246.39. The company reported a decline in net sales.
The insider purchases may indicate confidence, but the decline in net sales could negatively impact the stock price.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100